Cercar
01/01/2023
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion (vol 30, pg 51, 2023)
Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion (vol 30, pg 51, 2023). CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00564-0. PMID:36460806. IF:4.800(Q1/2D).
01/01/2023
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
Cruz D., Rodríguez-Romanos R., González-Bartulos M., García-Cadenas I., de la Cámara R., Heras I., Buño I., Santos N., Lloveras N., Velarde P., Tuset E., Martínez C., González M., Sanz G.F., Ferrá C., Sampol A., Coll R., Pérez-Simón J.A., López-Jiménez J., Jurado M., Gallardo D.. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1066393. PMID:36742309. IF:5.700(Q1/3D).
01/01/2023
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Kwon M., Iacoboni G., Reguera J.L., López Corral L., Morales R.H., Ortiz-Maldonado V., Guerreiro M., Caballero A.C., Domínguez M.L.G., Pina J.M.S., Mussetti A., Sancho J.M., Bastos-Oreiro M., Catala E., Delgado J., Henriquez H.L., Sanz J., Calbacho M., Bailén R., Carpio C., Ribera J.M., Sureda A., Briones J., Hernandez-Boluda J.C., Cebrián N.M., Martin J.L.D., Martín A., Barba P.. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. HAEMATOLOGICA. 2023; 108(1)DOI:10.3324/haematol.2022.280805. PMID:35770532. IF:10.100(Q1/2D).
01/01/2023
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia
Moia R., Dondolin R., De Propris M.S., Talotta D., Mouhssine S., Perutelli F., Reda G., Mattiello V., Rigolin G.M., Motta M., Olivieri J., Fanin R., Perbellini O., Ferrarini I., Mauro F.R., Del Giudice I., Laurenti L., Tomasso A., Gentile M., Frustaci A.M., Tedeschi A., Gozzetti A., Stelitano C., Visco C., Moreno C., Forconi F., Marasca R., Coscia M., Rossi D., Foà R., Gaidano G.. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. HEMATOLOGICAL ONCOLOGY. 2023; 41(3)DOI:10.1002/hon.3080. PMID:36190298. IF:3.300(Q2/4D).
01/01/2023
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Dickinson M.J., Barba P., Jäger U., Shah N.N., Blaise D., Briones J., Shune L., Boissel N., Bondanza A., Mariconti L., Marchal A.-L., Quinn D.S., Yang J., Price A., Sohoni A., Treanor L.M., Orlando E.J., Mataraza J., Davis J., Lu D., Zhu X., Engels B., Moutouh-de Parseval L., Brogdon J.L., Moschetta M., Flinn I.W.. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discovery. 2023; 13(9)DOI:10.1158/2159-8290.CD-22-1276. PMID:37249512. IF:30.600(Q1/1D).
01/01/2023
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study
Solano C., Castro-Rebollo P., Pérez-Martínez A., López-Corral L., Barba-Suñol P., Kwon M., Ortiz V., Sanz-Caballer J., Caballero A.C., Martínez J., Cedillo Á., Sureda A.. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study. BMJ Open. 2023; 13(7)DOI:10.1136/bmjopen-2022-071371. PMID:37491085. IF:2.400(Q1/3D).
01/01/2023
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Muñoz A., Ay C., Grilz E., López S., Font C., Pachón V., Castellón V., Martínez-Marín V., Salgado M., Martínez E., Calzas J., Ortega L., Rupérez A., Salas E., Pabinger I., Soria J.M.. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(16)DOI:10.1200/JCO.22.00255. PMID:36730884. IF:42.100(Q1/1D).
01/01/2023
Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
Bailén R., Alenda R., Herruzo-Delgado B., Acosta-Fleitas C., Vallés A., Esquirol A., Fonseca M., Solán L., Sánchez-Vadillo I., Bautista G., Bento L., López-Godino O., Pérez-Martínez A., Torrent A., Zanabili J., Calbacho M., Moreno M.Á., Pascual-Cascón M.J., Guerra-Domínguez L., Chinea A., García-Cadenas I., López-Corral L., Boix-Giner F., López Lorenzo J.L., Humala K., Duarte R., Sampol A., Heras I., Vicario J.L., Balas A., Oarbeascoa G., Fernández-Caldas P., Anguita J., Kwon M.. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1165759. PMID:37304258. IF:5.700(Q1/3D).